Literature DB >> 21595606

Evaluating the effects of genetic variants of DNA repair genes using cytogenetic mutagen sensitivity approaches.

Sherif Z Abdel-Rahman1, Randa A El-Zein.   

Abstract

Mutagen sensitivity, measured in short-term cultures of peripheral blood lymphocytes by cytogenetic endpoints, is an indirect measure for DNA repair capacity and has been used for many years as a biomarker for intrinsic susceptibility for cancer. In this article, we briefly give an overview of the different cytogenetic mutagen sensitivity approaches that have been used successfully to evaluate the biological effects of polymorphisms in DNA repair genes based on a current review of the literature and based on the need for biomarkers that would allow the characterization of the biological and functional significance of such polymorphisms. We also address some of the future challenges facing this emerging area of research.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21595606      PMCID: PMC3142279          DOI: 10.3109/1354750X.2011.577237

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  118 in total

1.  XPD polymorphisms: effects on DNA repair proficiency.

Authors:  R M Lunn; K J Helzlsouer; R Parshad; D M Umbach; E L Harris; K K Sanford; D A Bell
Journal:  Carcinogenesis       Date:  2000-04       Impact factor: 4.944

2.  Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk.

Authors:  X Wu; H Yu; C I Amos; W K Hong; M R Spitz
Journal:  Growth Horm IGF Res       Date:  2000-04       Impact factor: 2.372

Review 3.  Mutation and epigenetic molecular clocks in cancer.

Authors:  Darryl Shibata
Journal:  Carcinogenesis       Date:  2010-11-12       Impact factor: 4.944

4.  Low level occupational exposure to styrene: its effects on DNA damage and DNA repair.

Authors:  Sirilak Wongvijitsuk; Panida Navasumrit; Udomratana Vattanasit; Varabhorn Parnlob; Mathuros Ruchirawat
Journal:  Int J Hyg Environ Health       Date:  2010-10-27       Impact factor: 5.840

5.  Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. European Study Group on Cytogenetic Biomarkers and Health.

Authors:  S Bonassi; L Hagmar; U Strömberg; A H Montagud; H Tinnerberg; A Forni; P Heikkilä; S Wanders; P Wilhardt; I L Hansteen; L E Knudsen; H Norppa
Journal:  Cancer Res       Date:  2000-03-15       Impact factor: 12.701

6.  The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK.

Authors:  S Z Abdel-Rahman; R A El-Zein
Journal:  Cancer Lett       Date:  2000-10-16       Impact factor: 8.679

7.  Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families.

Authors:  A Rothfuss; P Schütz; S Bochum; T Volm; E Eberhardt; R Kreienberg; W Vogel; G Speit
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

Review 8.  The in vitro micronucleus technique.

Authors:  M Fenech
Journal:  Mutat Res       Date:  2000-11-20       Impact factor: 2.433

Review 9.  Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review.

Authors:  M Berwick; P Vineis
Journal:  J Natl Cancer Inst       Date:  2000-06-07       Impact factor: 13.506

10.  Risk of cancer in an occupationally exposed cohort with increased level of chromosomal aberrations.

Authors:  Z Smerhovsky; K Landa; P Rössner; M Brabec; Z Zudova; N Hola; Z Pokorna; J Mareckova; D Hurychova
Journal:  Environ Health Perspect       Date:  2001-01       Impact factor: 9.031

View more
  2 in total

1.  Association between XRCC3 Thr241Met polymorphism and colorectal cancer risk.

Authors:  ZhiZhen Wang; Wencheng Zhang
Journal:  Tumour Biol       Date:  2013-03-17

2.  DNA repair in cancer development and aging.

Authors:  Hua Zhao; Bernard F Fuemmeler; Jie Shen
Journal:  Aging (Albany NY)       Date:  2021-10-26       Impact factor: 5.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.